Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown.In an integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) in adults with active Crohn's disease. In the induction trial, 368 patients were randomly assigned to receive vedolizumab or placebo at weeks 0 and 2 (cohort 1), and 747 patients received open-label vedolizumab at weeks 0 and 2 (cohort 2);...